[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367287-105":59,"doc-detail-367287-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteogenomic-discovery-of-rb1-defective-phenocopy-in-cancer-predicts-disease-outcome-response-to-treatment-and-therapeutic-targets","Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets","","Genomic truncating mutations and deletions in RB1 dysregulate the RB pathway across many cancer types. This work proposes an integrative proteogenomic strategy to identify cancers with RB-pathway dysfunction, including a pan-cancer subset termed “RBness” that lacks RB1 genomic defects yet phenocopies the RB1-defective transcriptional profile. RBness correlates with patient outcome and chemotherapy response across cancers and predicts CDK4/6 inhibitor response in estrogen-positive breast cancer. Functional screens in isogenic models show RBness cancers also phenocopy synthetic lethal vulnerabilities of RB1-defective cells, supporting a molecular rationale for targeted therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteogenomic-discovery-of-rb1-defective-phenocopy-in-cancer-predicts-disease-outcome-response-to-treatment-and-therapeutic-targets/367287/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteogenomic-discovery-of-rb1-defective-phenocopy-in-cancer-predicts-disease-outcome-response-to-treatment-and-therapeutic-targets/367287.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study propose to identify cancers with RB pathway dysfunction?","Question",{"text":112,"@type":113},"It proposes an integrative proteogenomic approach to predict cancers showing dysregulation of the RB pathway, including cases without RB1 genomic defects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are “RBness” cancers?",{"text":117,"@type":113},"“RBness” cancers are a subset that lack RB1 genomic defects but phenocopy the transcriptional profile of RB1-defective cancers, behaving as a pan-cancer phenomenon.",{"name":119,"@type":110,"acceptedAnswer":120},"How is RB1 status linked to treatment response mentioned in the text?",{"text":121,"@type":113},"The text links RB1 deleterious mutations and deletions to poor overall survival and chemotherapy response, and it reports that RBness predicts CDK4/6 inhibitor response in estrogen-positive breast cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367287,1790269637,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","CANCER  \nProteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets  \nJacopo Iacovacci1,2, Rachel Brough1,3, Fatemeh Ahmadi Moughari1, John Alexander1,  \nHarriet Kemp1, Andrew N. J. Tutt1, Rachael Natrajan1, Christopher J. Lord1,3*, Syed Haider1*  \nGenomic defects caused by truncating mutations or deletions in the Retinoblastoma tumor suppressor gene (RB1) are frequently observed in many cancer types leading to dysregulation of the RB pathway. Here, we propose an integrative proteogenomic approach that predicts cancers with dysregulation in the RB pathway. A subset of these cancers, which we term as“RBness,” lack RB1 genomic defects and yet phenocopy the transcriptional profile of RB1-defective cancers. We report RBness as a pan-cancer phenomenon, associated with patient outcome and chemotherapy response in multiple cancer types, and predictive ofCDK4/6 inhibitor response in estrogen-positive breast cancer. Using RNA interference and a CRISPR-Cas9 screen in isogenic models, we find that RBness cancers also phenocopy synthetic lethal vulnerabilities of cells with RB1 genomic defects. In summary, our findings suggest that dysregulation ofthe RB pathway in cancers lacking RB1 genomic defects provides a molecular rationale for how these cancers could be treated.  \ncopyright © 2025 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nRB1 is a prototypic tumor suppressor gene that is frequently mutated and/or deleted in a variety of human cancers (1). RB1’s canonical role is in the regulation of the cell cycle, a function that is primarily mediated by its control over the E2F family of transcription factors (2) . The Rb protein recruits chromatin regulators via the LxCxE-binding cleft in its pocket domain, which in turn controls the expression of E2F target genes (3) . The LxCxE motif that enables interactions with histone deacetylases (HDACs) and chromatin modelers is independent of Rb’s E2F binding domain and therefore adds further complexity to E2F-mediated functionality of Rb (4) . For instance, deacetylation of histones by HDACs is necessary forthe Rb-mediated repression of genes activated in G1 cell cycle. Furthermore, Rb also binds to histone methyltransferases and histone demethylases, suggesting an epigenetic role in the maintenance of heterochromatin organization and stability (4). In summary, the Rb protein complex is multifunctional (2) and regulates a plethora of biological processes from chromatin regulation and stability, senescence, apoptosis, and mitochondrial function (1, 5, 6). In part, at least, the loss of Rb function in tumor cells results in augmented cell proliferation due to dysregulation of the G1-S cell cycle checkpoint (1, 7) .  \nFrom a clinical perspective, RB1 deleterious mutations and deletions are associated with poor overall survival (OS) and response to chemotherapy in cancers such as those of the breast, lung, and prostate (8) . For example, in triple-negative breast cancer (TNBC), a highly aggressive subtype with poor survival properties (5-year OS rate of 77%), approximately 13% of tumors harbor mutations or deletions ofthe RB1 gene. Similarly, mutational and structural defects in RB1 are frequently observed in many cancers accounting for up to 25% of bladder cancer (BLCA) and sarcomas (9) . Recent studies  \n1the Breast cancer now toby Robins Research centre, the Institute of cancer Research, london SW3 6JB, UK. 2data Science Unit, Fondazione IRccS Istituto nazionale dei tumori di Milano, Milano 20133, Italy. 3cRUK Gene Function laboratory, the Institute of cancer Research, london SW3 6JB, UK.  \n*corresponding [author. email:](author. email:) [chris.lord@icr.ac.uk](chris.lord@icr.ac.uk) (c.J.l.); [syed.haider@icr.ac.uk](syed.haider@icr.ac","cbCainkLfL9iTvXp","https://ap.wps.com/l/cbCainkLfL9iTvXp","pdf",3278426,"English","# Introduction\n## RB1 role in cell-cycle and gene regulation\n## Clinical relevance of RB1 status\n## Prior transcriptomic RB signatures and limitations","[{\"question\":\"What does the study propose to identify cancers with RB pathway dysfunction?\",\"answer\":\"It proposes an integrative proteogenomic approach to predict cancers showing dysregulation of the RB pathway, including cases without RB1 genomic defects.\"},{\"question\":\"What are “RBness” cancers?\",\"answer\":\"“RBness” cancers are a subset that lack RB1 genomic defects but phenocopy the transcriptional profile of RB1-defective cancers, behaving as a pan-cancer phenomenon.\"},{\"question\":\"How is RB1 status linked to treatment response mentioned in the text?\",\"answer\":\"The text links RB1 deleterious mutations and deletions to poor overall survival and chemotherapy response, and it reports that RBness predicts CDK4/6 inhibitor response in estrogen-positive breast cancer.\"}]","Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets | PDF",1790170092,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb46cd140e10ee240ccd7cab9da993d9.webp",983,1250,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d779f35193acb38980c8d0784536d472.webp",982,1249,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/893e70671f9d99ff04a028a7b5fb5cf9.webp",981,1248,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83d3cfa6f200f8639f0a27089112266f.webp",980,1247]